Aristo Bio-Tech & Lifescience Complete Financial Statements

In FYNone, Aristo Bio-Tech & Lifescience (ARISTO) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 1.3% and ROE of 10.8%. Full financial statements from FY2016 to FY2025 (10 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see ARISTO company profile.

10 Years of Data
2025 - 2016

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 1.25% 2025 data
EBITDA Margin 3.13% 2025 data
Operating Margin 3.00% 2025 data
Return on Assets 2.84% 2025 data
Return on Equity 10.81% 2025 data

Balance Sheet Ratios

Current Ratio 14.50 2025 data
Equity Ratio 26.24% 2025 data
Asset Turnover 2.26 2025 data

ARISTO Revenue, Net Profit & EBITDA — Year-on-Year Growth

ARISTO YoY (March 2025 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+11.0%
Year-over-Year
Equity Growth
+8.8%
Year-over-Year
Operating Cash Flow Growth
+25.0%
Year-over-Year
Investing Cash Flow Growth
+28.6%
Year-over-Year
Financing Cash Flow Growth
-100.0%
Year-over-Year

ARISTO Income Statement — Revenue, EBITDA & Net Profit

Aristo Bio-Tech & Lifescience revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 1.3%. Explore ARISTO Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Revenue 0 319 245 218 166 167 201 202 272 161 58
Expenses 0 309 237 209 161 163 197 195 264 158 56
EBITDA 0 10 9 9 5 4 5 7 8 4 1
Operating Profit Margin % 0.00% 3.00% 3.00% 4.00% 3.00% 3.00% 2.00% 3.00% 3.00% 2.00% 2.00%
Depreciation 0 3 2 2 1 1 1 1 1 0 0
Interest 0 2 2 3 2 2 3 2 2 1 1
Profit Before Tax 0 6 5 5 2 2 1 4 6 3 1
Tax 0 1 2 1 1 0 0 1 2 1 0
Net Profit 0 4 4 4 1 1 1 3 4 2 0
Earnings Per Share (₹) 0.00 5.97 5.72 6.72 2.87 2.15 2.02 5.66 37.41 18.53 3.98

ARISTO Balance Sheet — Assets, Liabilities & Shareholders' Equity

ARISTO total assets ₹141 Cr, total equity ₹37 Cr, total liabilities ₹ Cr (2025) — ROE 10.8%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
ASSETS
Total Assets 141 127 100 77 81 88 91 89 87 27
Current Assets 116 105 83 63 69 77 81 81 84 25
Fixed Assets 24 22 16 14 12 8 8 3 2 2
Capital Work in Progress 0 0 1 0 0 3 2 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0
Other Assets 117 106 83 63 69 77 81 86 85 25
LIABILITIES
Total Liabilities
Current Liabilities 8 10 10 11 12 11 7 11 5 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 37 34 30 15 13 12 11 9 5 3
Share Capital 7 7 7 5 5 5 5 1 1 1
Reserves & Surplus 31 27 23 10 8 7 6 8 4 2

ARISTO Cash Flow Statement — Operating, Investing & Financing

Aristo Bio-Tech & Lifescience operating cash flow ₹10 Cr, investing ₹-5 Cr, financing ₹-4 Cr, net cash flow ₹1 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017
Operating Activities 10 8 -3 7 2 1 8 1 -4
Investing Activities -5 -7 -4 -3 -2 -2 -2 -5 0
Financing Activities -4 -2 8 -3 -1 1 -6 4 4
Net Cash Flow 1 -1 1 0 0 0 0 0 0